{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Das R"],"funding":["CSB Development Fund","National Cancer Institute","Karin Grunebaum Cancer Research Foundation","NCI NIH HHS"],"pagination":["e2400633"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11740962"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["9(1)"],"pubmed_abstract":["Lipid nanoparticles encapsulating mRNA (LNP-mRNA) revolutionized medicine over the past several years. While clinically approved indications currently focus on infectious disease vaccination, LNP-mRNA based treatments also hold promise for cancer immunotherapy. However, the route of dosing may impact treatment efficacy, safety, and dose. To minimize adverse effects, it is hypothesized that LNP-mRNA can be used to activate and engineer dendritic cells (DC) ex vivo before re-administration of these cells. Here, it is shown that LNP-mRNA engineered DCs can indeed vaccinate recipient mice. Vaccinated mice showed strong anti-tumor T cell responses, rejected tumor challenge, and displayed no evidence of toxicity. Further, it is found that DC specific ablation of the immune activating kinase NFkB"],"journal":["Small methods"],"pubmed_title":["Lipid Nanoparticle-mRNA Engineered Dendritic Cell Based Adoptive Cell Therapy Enhances Cancer Immune Response."],"pmcid":["PMC11740962"],"funding_grant_id":["T32 CA079443","T32CA079443","R33 CA277820"],"pubmed_authors":["Parvanian S","Das R","Garris CS","Weissleder R","Ge X","Fei F"],"additional_accession":[]},"is_claimable":false,"name":"Lipid Nanoparticle-mRNA Engineered Dendritic Cell Based Adoptive Cell Therapy Enhances Cancer Immune Response.","description":"Lipid nanoparticles encapsulating mRNA (LNP-mRNA) revolutionized medicine over the past several years. While clinically approved indications currently focus on infectious disease vaccination, LNP-mRNA based treatments also hold promise for cancer immunotherapy. However, the route of dosing may impact treatment efficacy, safety, and dose. To minimize adverse effects, it is hypothesized that LNP-mRNA can be used to activate and engineer dendritic cells (DC) ex vivo before re-administration of these cells. Here, it is shown that LNP-mRNA engineered DCs can indeed vaccinate recipient mice. Vaccinated mice showed strong anti-tumor T cell responses, rejected tumor challenge, and displayed no evidence of toxicity. Further, it is found that DC specific ablation of the immune activating kinase NFkB","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jan","modification":"2026-06-06T07:38:26.238Z","creation":"2026-05-27T03:11:46.525Z"},"accession":"S-EPMC11740962","cross_references":{"pubmed":["39039995"],"doi":["10.1002/smtd.202400633"]}}